DESTINY MEDIA TECHNOLOGIES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that DESTINY MEDIA TECHNOLOGIES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $4.52M | Nov 24, 2025 |
| FY2025 | Aug 31, 2024 | $4.42M | Nov 24, 2025 |
| FY2024 | Aug 31, 2023 | $4.03M | Nov 21, 2024 |
| FY2023 | Aug 31, 2022 | $4.02M | Nov 28, 2023 |
| FY2022 | Aug 31, 2021 | $4.17M | Nov 14, 2022 |
| FY2021 | Aug 31, 2020 | $3.82M | Nov 23, 2021 |
| FY2020 | Aug 31, 2019 | $3.81M | Nov 18, 2020 |
| FY2019 | Aug 31, 2018 | $3.61M | Nov 18, 2019 |
| FY2018 | Aug 31, 2017 | $3.45M | Nov 27, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $3.84M | Nov 24, 2025 |
| FY2025 | Aug 31, 2024 | $3.81M | Nov 24, 2025 |
| FY2024 | Aug 31, 2023 | $3.52M | Nov 21, 2024 |
| FY2023 | Aug 31, 2022 | $3.37M | Nov 28, 2023 |
| FY2022 | Aug 31, 2021 | $3.78M | Nov 14, 2022 |
| FY2021 | Aug 31, 2020 | $3.51M | Nov 23, 2021 |
| FY2020 | Aug 31, 2019 | $3.50M | Nov 18, 2020 |
| FY2019 | Aug 31, 2018 | $3.31M | Nov 18, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | ($637.9K) | Nov 24, 2025 |
| FY2025 | Aug 31, 2024 | $111.8K | Nov 24, 2025 |
| FY2024 | Aug 31, 2023 | $335.1K | Nov 21, 2024 |
| FY2023 | Aug 31, 2022 | $149.1K | Nov 28, 2023 |
| FY2022 | Aug 31, 2021 | $382.5K | Nov 14, 2022 |
| FY2021 | Aug 31, 2020 | $169.4K | Nov 23, 2021 |
| FY2020 | Aug 31, 2019 | $610.8K | Nov 18, 2020 |
| FY2019 | Aug 31, 2018 | $656.3K | Nov 18, 2019 |
| FY2018 | Aug 31, 2017 | $288.8K | Nov 27, 2018 |
| FY2017 | Aug 31, 2016 | ($188.3K) | Nov 29, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | ($663.1K) | Nov 24, 2025 |
| FY2025 | Aug 31, 2024 | $60.6K | Nov 24, 2025 |
| FY2024 | Aug 31, 2023 | $301.2K | Nov 21, 2024 |
| FY2023 | Aug 31, 2022 | $133.3K | Nov 28, 2023 |
| FY2022 | Aug 31, 2021 | $378.5K | Nov 14, 2022 |
| FY2021 | Aug 31, 2020 | $145.0K | Nov 23, 2021 |
| FY2020 | Aug 31, 2019 | $581.1K | Nov 18, 2020 |
| FY2019 | Aug 31, 2018 | $649.4K | Nov 18, 2019 |
| FY2018 | Aug 31, 2017 | $274.4K | Nov 27, 2018 |
| FY2017 | Aug 31, 2016 | ($209.4K) | Nov 29, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $1.77M | Nov 24, 2025 |
| FY2025 | Aug 31, 2024 | $1.52M | Nov 24, 2025 |
| FY2024 | Aug 31, 2023 | $1.34M | Nov 21, 2024 |
| FY2023 | Aug 31, 2022 | $1.10M | Nov 28, 2023 |
| FY2022 | Aug 31, 2021 | $1.19M | Nov 14, 2022 |
| FY2021 | Aug 31, 2020 | $1.34M | Nov 23, 2021 |
| FY2020 | Aug 31, 2019 | $1.14M | Nov 18, 2020 |
| FY2019 | Aug 31, 2018 | $1.09M | Nov 18, 2019 |
| FY2018 | Aug 31, 2017 | $1.23M | Nov 27, 2018 |
| FY2017 | Aug 31, 2016 | $1.29M | Nov 29, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $65.2K | Nov 24, 2025 |
| FY2025 | Aug 31, 2024 | $429.2K | Nov 24, 2025 |
| FY2024 | Aug 31, 2023 | $705.6K | Nov 21, 2024 |
| FY2023 | Aug 31, 2022 | $307.2K | Nov 28, 2023 |
| FY2022 | Aug 31, 2021 | $528.9K | Nov 14, 2022 |
| FY2021 | Aug 31, 2020 | $272.2K | Nov 23, 2021 |
| FY2020 | Aug 31, 2019 | $804.5K | Nov 18, 2020 |
| FY2019 | Aug 31, 2018 | $1.09M | Nov 18, 2019 |
| FY2018 | Aug 31, 2017 | $695.6K | Nov 27, 2018 |
| FY2017 | Aug 31, 2016 | ($162.8K) | Nov 29, 2017 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $29.1K | Nov 24, 2025 |
| FY2025 | Aug 31, 2024 | $8.2K | Nov 24, 2025 |
| FY2024 | Aug 31, 2023 | $585.5K | Nov 21, 2024 |
| FY2023 | Aug 31, 2022 | $326.3K | Nov 28, 2023 |
| FY2022 | Aug 31, 2021 | $44.8K | Nov 14, 2022 |
| FY2021 | Aug 31, 2020 | $64.1K | Nov 23, 2021 |
| FY2020 | Aug 31, 2019 | $163.0K | Nov 18, 2020 |
| FY2019 | Aug 31, 2018 | $116.5K | Nov 18, 2019 |
| FY2018 | Aug 31, 2017 | $63.3K | Nov 27, 2018 |
| FY2017 | Aug 31, 2016 | $73.1K | Nov 29, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $2.97M | Nov 24, 2025 |
| FY2025 | Aug 31, 2024 | $3.69M | Nov 24, 2025 |
| FY2024 | Aug 31, 2023 | $3.89M | Nov 21, 2024 |
| FY2023 | Aug 31, 2022 | $3.57M | Nov 28, 2023 |
| FY2022 | Aug 31, 2021 | $3.87M | Nov 14, 2022 |
| FY2021 | Aug 31, 2020 | $3.81M | Nov 23, 2021 |
| FY2020 | Aug 31, 2019 | $3.64M | Nov 18, 2020 |
| FY2019 | Aug 31, 2018 | $2.96M | Nov 18, 2019 |
| FY2018 | Aug 31, 2017 | $2.24M | Nov 27, 2018 |
| FY2017 | Aug 31, 2016 | $1.85M | Nov 29, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $544.3K | Nov 24, 2025 |
| FY2025 | Aug 31, 2024 | $522.9K | Nov 24, 2025 |
| FY2024 | Aug 31, 2023 | $412.1K | Nov 21, 2024 |
| FY2023 | Aug 31, 2022 | $457.1K | Nov 28, 2023 |
| FY2022 | Aug 31, 2021 | $748.1K | Nov 14, 2022 |
| FY2021 | Aug 31, 2020 | $949.6K | Nov 23, 2021 |
| FY2020 | Aug 31, 2019 | $506.1K | Nov 18, 2020 |
| FY2019 | Aug 31, 2018 | $445.6K | Nov 18, 2019 |
| FY2018 | Aug 31, 2017 | $351.9K | Nov 27, 2018 |
| FY2017 | Aug 31, 2016 | $362.5K | Nov 29, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $2.42M | Nov 24, 2025 |
| FY2025 | Aug 31, 2024 | $3.17M | Nov 24, 2025 |
| FY2025 | Aug 31, 2023 | $3.47M | Nov 24, 2025 |
| FY2024 | Aug 31, 2022 | $3.11M | Nov 21, 2024 |
| FY2023 | Aug 31, 2021 | $3.12M | Nov 28, 2023 |
| FY2022 | Aug 31, 2020 | $2.86M | Nov 14, 2022 |
| FY2021 | Aug 31, 2019 | $3.13M | Nov 23, 2021 |
| FY2020 | Aug 31, 2018 | $2.52M | Nov 18, 2020 |
| FY2019 | Aug 31, 2017 | $1.89M | Nov 18, 2019 |
| FY2018 | Aug 31, 2016 | $1.49M | Nov 27, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | ($5.83M) | Nov 24, 2025 |
| FY2025 | Aug 31, 2024 | ($5.19M) | Nov 24, 2025 |
| FY2024 | Aug 31, 2023 | ($5.30M) | Nov 21, 2024 |
| FY2023 | Aug 31, 2022 | ($5.64M) | Nov 28, 2023 |
| FY2022 | Aug 31, 2021 | ($5.79M) | Nov 14, 2022 |
| FY2021 | Aug 31, 2020 | ($6.17M) | Nov 23, 2021 |
| FY2020 | Aug 31, 2019 | ($6.34M) | Nov 18, 2020 |
| FY2019 | Aug 31, 2018 | ($6.95M) | Nov 18, 2019 |
| FY2018 | Aug 31, 2017 | ($7.61M) | Nov 27, 2018 |
| FY2017 | Aug 31, 2016 | ($7.90M) | Nov 29, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $1.12M | Nov 24, 2025 |
| FY2025 | Aug 31, 2024 | $1.48M | Nov 24, 2025 |
| FY2024 | Aug 31, 2023 | $2.00M | Nov 21, 2024 |
| FY2023 | Aug 31, 2022 | $2.10M | Nov 28, 2023 |
| FY2022 | Aug 31, 2021 | $2.75M | Nov 14, 2022 |
| FY2021 | Aug 31, 2020 | $1.84M | Nov 23, 2021 |
| FY2021 | Aug 31, 2019 | $2.51M | Nov 23, 2021 |
| FY2020 | Aug 31, 2018 | $1.10M | Nov 18, 2020 |
| FY2019 | Aug 31, 2017 | $1.34M | Nov 18, 2019 |
| FY2018 | Aug 31, 2016 | $662.7K | Nov 27, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 0 | Nov 24, 2025 |
| FY2025 | Aug 31, 2024 | 0 | Nov 24, 2025 |
| FY2024 | Aug 31, 2023 | 0 | Nov 21, 2024 |
| FY2023 | Aug 31, 2022 | 0 | Nov 28, 2023 |
| FY2022 | Aug 31, 2021 | 0 | Nov 14, 2022 |
| FY2021 | Aug 31, 2020 | 0 | Nov 23, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 0 | Nov 24, 2025 |
| FY2025 | Aug 31, 2024 | 0 | Nov 24, 2025 |
| FY2024 | Aug 31, 2023 | 0 | Nov 21, 2024 |
| FY2023 | Aug 31, 2022 | 0 | Nov 28, 2023 |
| FY2022 | Aug 31, 2021 | 0 | Nov 14, 2022 |
| FY2021 | Aug 31, 2020 | 0 | Nov 23, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 9.64M | Nov 24, 2025 |
| FY2025 | Aug 31, 2024 | 9.64M | Nov 24, 2025 |
| FY2024 | Aug 31, 2023 | 10.10M | Nov 21, 2024 |
| FY2023 | Aug 31, 2022 | 10.12M | Nov 28, 2023 |
| FY2022 | Aug 31, 2021 | 10.27M | Nov 14, 2022 |
| FY2021 | Aug 31, 2020 | 10.45M | Nov 23, 2021 |
| FY2020 | Aug 31, 2019 | 11.00M | Nov 18, 2020 |
| FY2019 | Aug 31, 2018 | 11.00M | Nov 18, 2019 |
| FY2018 | Aug 31, 2017 | 55.01M | Nov 27, 2018 |
| FY2017 | Aug 31, 2016 | 55.01M | Nov 29, 2017 |